Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ascorbic acid, quantity: 500 mg; zinc gluconate, quantity: 14 mg (equivalent: zinc, qty 2 mg); echinacea purpurea, quantity: 22.22 mg (equivalent: echinacea purpurea, qty 1000 mg); allium sativum, quantity: 8.33 mg (equivalent: allium sativum, qty 100 mg) - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400; vanillin; garlic bulb powder; dl-alpha-tocopherol; maize starch; silicon dioxide; croscarmellose sodium; crospovidone; microcrystalline cellulose; calcium hydrogen phosphate dihydrate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin aspart, quantity: 3.5 mg/ml - injection, solution - excipient ingredients: metacresol; phenol; polysorbate 20; sodium hydroxide; hydrochloric acid; water for injections; zinc chloride; sodium chloride - for the treatment of diabetes mellitus

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; histidine hydrochloride monohydrate; sucrose; polysorbate 80; histidine - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 100 mg - injection, concentrated - excipient ingredients: histidine; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - biphasic isophane human insulin 75/25 (rdna origin) - suspension for injection sc / im - 100iu/ml

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - biphasic isophane human insulin 75/25 (rdna origin) - suspension for injection sc / im - 100iu/ml

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - biphasin isophane human insulin 70/30 - suspension for injection sc - 100iu/ml

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - biphasin isophane human insulin 70/30 - suspension for injection sc - 100iu/ml

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - insulin glargine - solution for injection sc - 100 iu/ml

Philippines - English - FDA (Food And Drug Administration)

sanofi-aventis phils inc - insulin human (rdna) - solution for injection sv/iv - 100 iu/ml